Please login to order a test.
- Antihemophilic Factor C
- Plasma Thromboplastin Antecedent (PTA)
Evaluate isolated aPTT prolongation and to document specific factor deficiency6-8
Direct Xa or thrombin inhibitor therapy may cause factitiously low results.
Factor XI activity is determined utilizing an aPTT-based one-stage clotting time assay. Factor XI-depleted plasma is used as the substrate, and the clotting time with the patient plasma is compared to the clotting time of normal pooled plasma.
Factor XI is a 160 kilodalton glycoprotein proenzyme that is produced by the liver and megakaryocytes.6-8 Factor XI's plasma concentration is 4-6 mg/mL and half-life is about 60 hours.6 Hereditary factor XI deficiency, referred to as hemophilia C, is transmitted as an autosomal recessive mutation.6-8 This condition affects both males and females and the majority of reported cases have been diagnosed in Ashkenazi Jews.6,7 As many as 11% of Ashkenazi Jews will be heterozygous for factor XI deficiency and up to 0.3% will be homozygous.8 Individuals who are heterozygous for factor XI deficiency mutation typically have levels between 30% to 60% and homozygotes have levels <20%.8 The bleeding associated with factor XI deficiency is generally not as severe as that found with hemophilia A or B.7 Severity of bleeding does not always correlate with the plasma level of factor XI.6,7 Individuals with factor XI deficiency can suffer from easy bruising, epistaxis, hematuria, and menorrhagia.6,7 Excessive bleeding postpartum and after oral cavity surgery can occur.7
Acquired inhibitors of factor XI are very rare.6 Spontaneous autoantibodies are more common and generally occur in patients with underlying autoimmune disorders or in patients treated with chlorpromazine.6
Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.1 Evacuated collection tubes must be filled to completion to ensure a proper blood-to-anticoagulant ratio.2,3 The sample should be mixed immediately by gentle inversion at least six times to ensure adequate mixing of the anticoagulant with the blood. A discard tube is not required prior to collection of coagulation samples unless the sample is collected using a winged (butterfly) collection system. With a winged blood collection set a discard tube should be drawn first to account for the dead space of the tubing and prevent under-filling of the evacuated tube.4,5 When noncitrate tubes are collected for other tests, collect sterile and nonadditive (red-top) tubes prior to citrate (blue-top) tubes. Any tube containing an alternative anticoagulant should be collected after the blue-top tube. Gel-barrier tubes and serum tubes with clot initiators should also be collected after the citrate tubes. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Please print and use the Volume Guide for Coagulation Testing to ensure proper draw volume.
Causes for Rejection
Severe hemolysis; improper labeling; clotted specimen; specimen diluted with IV fluids; samples thawed in transit; improper sample type; sample out of stability
If the patient's hematocrit exceeds 55%, the volume of citrate in the collection tube must be adjusted. Refer to Coagulation Collection Procedures for directions.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|086314||Factor XI Activity||3226-8||086314||Factor XI Activity||%||3226-8|